Floatz logo

117 assets in Colorectal Neoplasm

Therapeutic assets addressing Colorectal Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Fluorouracilum
Colorectal Neoplasm
Rutgers, The State University of New JerseyP4BBB (74)
Oxaliplatin
Colorectal Neoplasm
Peking University Cancer Hospital & InstituteP4BBB (74)
Irinotecan
Colorectal Neoplasm
Shanghai Zhongshan HospitalP4BBB (73)
Capecitabine
Colorectal Neoplasm
Rutgers, The State University of New JerseyP4BB (71)
Regorafenib
Colorectal Neoplasm
Sergey Orlov, MDP4BB (71)
Nivolumab
Colorectal Neoplasm
Bristol-Myers SquibbP3BB (70)
Vandazole
Colorectal Neoplasm
Helsinki University Central HospitalP4BB (69)
Cetuximab
Colorectal Neoplasm
Zhejiang UniversityP4BB (64)
S-1
Colorectal Neoplasm
Fudan UniversityP2BB (64)
Cyclophosphamide
Colorectal Neoplasm
PfizerP3B (63)
Endostatin
Colorectal Neoplasm
First Affiliated Hospital Xi'an Jiaotong UniversityP3B (63)
Floxuridine
Colorectal Neoplasm
The Netherlands Cancer InstituteP3B (63)
Levofolinic Acid
Colorectal Neoplasm
Janssen Research & Development, LLCP3B (63)
Macrogols
Colorectal Neoplasm
Helsinki University Central HospitalP4B (63)
Neomycin
Colorectal Neoplasm
Helsinki University Central HospitalP4B (63)
Pembrolizumab
Colorectal Neoplasm
GV20 TherapeuticsP3B (63)
Atezolizumab
Colorectal Neoplasm
Cancer Research UKP2/3B (62)
Tipiracil
Colorectal Neoplasm
Shanghai Zhongshan HospitalP3B (62)
Lenvatinib
Colorectal Neoplasm
Eisai Inc.P3B (61)
Panitumumab
Colorectal Neoplasm
Grupo Espanol Multidisciplinario del Cancer DigestivoP3B (61)
Trastuzumab
Colorectal Neoplasm
Cancer Research UKP3B (60)
Trifluridine
Colorectal Neoplasm
Shanghai Zhongshan HospitalP3B (60)
Adriamycin
Colorectal Neoplasm
Eisai Inc.P2B (59)
Etodolac
Colorectal Neoplasm
Assaf-Harofeh Medical CenterP3B (59)
Sgm-101
Colorectal Neoplasm
Leiden University Medical CenterP3B (59)
Sodium Picosulfate Hydrate
Colorectal Neoplasm
Nova Scotia Health AuthorityP4B (59)
Tas-102
Colorectal Neoplasm
Bristol-Myers SquibbP3B (59)
Apsolol
Colorectal Neoplasm
Assaf-Harofeh Medical CenterP3B (58)
Cis-Diamminedichloroplatinum Ii
Colorectal Neoplasm
PfizerP2B (58)
Ipilimumab
Colorectal Neoplasm
Gritstone bio, Inc.P2/3B (58)
Grt-C901
Colorectal Neoplasm
Gritstone bio, Inc.P2/3B (57)
Grt-R902
Colorectal Neoplasm
Gritstone bio, Inc.P2/3B (57)
Carboplatin
Colorectal Neoplasm
PfizerP2B (56)
Trametinib
Colorectal Neoplasm
Cancer Research UKP2/3CCC (55)
Amivantamab-Vmjw
Colorectal Neoplasm
Janssen Research & Development, LLCP3CCC (54)
Eflornithine
Colorectal Neoplasm
SWOG Cancer Research NetworkP3CCC (54)
Fruquintinib
Colorectal Neoplasm
Zhejiang UniversityP2CCC (54)
Jianpi Huatan Dispensing Granule
Colorectal Neoplasm
Xiyuan Hospital of China Academy of Chinese Medical SciencesP3CCC (54)
Nilotinib
Colorectal Neoplasm
National Cancer Institute (NCI)P2CCC (54)
pf-08634404
Colorectal Neoplasm
PfizerP3CCC (54)
Tislelizumab
Colorectal Neoplasm
Translational Research in OncologyP2CCC (54)
Tucatinib
Colorectal Neoplasm
Seagen, a wholly owned subsidiary of PfizerP3CCC (54)
ad5 cea vaccine
Colorectal Neoplasm
National Cancer Institute (NCI)P2CCC (53)
Adenovirus 5 Cea/Muc1/Brachyury Vaccine Tri-Ad5
Colorectal Neoplasm
National Cancer Institute (NCI)P2CCC (53)
Lomustine
Colorectal Neoplasm
Actuate Therapeutics Inc.P2CCC (53)
Muc-1 Peptide Vaccine
Colorectal Neoplasm
National Cancer Institute (NCI)P2CCC (53)
Nogapendekin Alfa
Colorectal Neoplasm
National Cancer Institute (NCI)P2CCC (53)
Sulindac
Colorectal Neoplasm
SWOG Cancer Research NetworkP3CCC (53)
Cobimetinib
Colorectal Neoplasm
Cancer Research UKP2/3CCC (52)
Dabrafenib
Colorectal Neoplasm
Cancer Research UKP2/3CCC (52)
Showing 1 to 50 of 117 assets
PreviousPage 1 of 3Next